RNA binding motif protein Y-linked family 1 member JGenealiases: []
Q-omics provides the consensus-scored RBMY1J profile across patient tissues and cancer cell-line models. RBMY1J expression is associated with patient survival in 3 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RBMY1J is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, RBMY1J RNA expression shows 2,464 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUSC, and TGCT as cancer lineages where RBMY1J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY1J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY1J survival associations across molecular data types. RBMY1J RNA expression shows survival associations in the most cancer types (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY1J RNA expression–survival associations across cancer types. High RBMY1J expression shows unfavorable associations in HNSC, THCA and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RBMY1J RNA expression.
This table summarizes RBMY1J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY1J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY1J shows lower tumor expression in LUSC and LUAD. The LUSC box plot shows higher RBMY1J RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p = .001).
This table shows molecular features associated with RBMY1J in patient tissues and cancer cell lines. In patient samples, RBMY1J shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMY1J RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
